BMP8A Antibody

What is BMP8A and what are its key biological functions?

BMP8A (Bone Morphogenetic Protein 8A) is a secreted ligand of the TGF-β superfamily that functions as a multifunctional growth factor. Research has identified several critical biological roles for BMP8A:

• Antiviral immunity: Acts as a positive regulator of antiviral immune responses by interacting with Alk6a to promote phosphorylation of Tbk1 and Irf3 through the p38 MAPK pathway, ultimately inducing type I interferons

• Cancer progression: Highly expressed in renal cell carcinoma and triple-negative breast cancer (TNBC), where it promotes cell proliferation, metastasis, and drug resistance

• Thermogenesis regulation: Increases the peripheral response of brown adipose tissue (BAT) to adrenergic stimulation while acting centrally in the hypothalamus to increase sympathetic output to BAT

• Reproductive development: Plays important roles in spermatogenesis through activation of both SMAD1/5/9 and SMAD2/3 pathways in spermatogonia

• Bone and cartilage formation: Induces cartilage and bone formation and may be involved in calcium regulation and bone homeostasis

What types of BMP8A antibodies are available for research applications?

Most commercially available BMP8A antibodies are rabbit polyclonal antibodies with varying epitope targets. The most common types include:

Most BMP8A antibodies recognize endogenous levels of the protein and are typically purified through immunogen affinity chromatography or protein A columns followed by peptide affinity purification .

How should I design validation experiments to confirm BMP8A antibody specificity?

When validating a BMP8A antibody for your research, employ multiple complementary approaches:

• Expression modulation tests: Compare antibody signals between:

  • Wild-type cells and BMP8A knockout models (e.g., TALEN-generated bmp8a-/- zebrafish)

  • Cells with normal expression versus those overexpressing BMP8A

  • Positive control tissues (e.g., reproductive tissues, BAT) versus negative control tissues

• Multiple detection methods: Validate with at least two techniques from:

  • Western blotting to confirm correct molecular weight (~45-50 kDa)

  • Immunohistochemistry with appropriate blocking controls

  • Immunofluorescence with subcellular localization assessment

  • Immunoprecipitation followed by mass spectrometry

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide (e.g., synthetic peptide from C-terminal region of human BMP8A) before application to your samples. Signal reduction confirms specificity .

• Cross-reactivity assessment: Test against related BMP family members, particularly BMP8B, which shares high sequence homology with BMP8A.

What are the optimal conditions for using BMP8A antibodies in Western blotting?

For successful BMP8A Western blotting, consider these methodological recommendations:

• Sample preparation:

  • For cellular samples: Lyse cells in RIPA buffer supplemented with protease and phosphatase inhibitors

  • For tissue samples: Homogenize in RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0)

  • Include 1 mM DTT and 1 mM PMSF to prevent disulfide bond formation that could affect epitope detection

• Protein loading and separation:

  • Load 20-40 μg of total protein per lane

  • Use 10-12% polyacrylamide gels for optimal separation

  • Include positive control (e.g., recombinant BMP8A protein)

• Transfer and blocking:

  • Transfer to PVDF membrane at 100V for 90 minutes in cold transfer buffer

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Antibody incubation:

  • Primary antibody: Dilute 1:500-1:1000 in 5% BSA in TBST; incubate overnight at 4°C

  • Secondary antibody: Anti-rabbit IgG HRP conjugate (1:4000 dilution) for 1 hour at room temperature

• Signal detection:

  • Use ECL substrate for standard detection

  • For low expression tissues, consider using enhanced chemiluminescence reagents

What considerations are important for immunohistochemistry (IHC) with BMP8A antibodies?

When performing IHC with BMP8A antibodies, follow these methodological guidelines:

• Tissue preparation:

  • Fix tissues in 4% paraformaldehyde for 24 hours

  • Paraffin embedding is suitable for most tissues

  • Use 4-6 μm tissue sections for optimal staining

• Antigen retrieval methods:

  • Heat-induced epitope retrieval in 10 mM citrate buffer (pH 6.0) for 20 minutes

  • Allow slides to cool to room temperature before proceeding

• Blocking procedure:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Block non-specific binding with 5% normal goat serum for 1 hour

• Antibody dilution and incubation:

  • Primary antibody: Dilute 1:100-1:200 in blocking buffer; incubate overnight at 4°C

  • Secondary antibody: Use appropriate HRP-conjugated secondary antibody (1:500) for 1 hour at room temperature

• Visualization:

  • Develop with DAB substrate for 3-5 minutes

  • Counterstain with hematoxylin for nuclear visualization

• Controls:

  • Include isotype control (rabbit IgG at same concentration as primary)

  • Include known positive tissue (e.g., kidney cancer tissue for BMP8A, which shows elevated expression)

How can I effectively study BMP8A signaling pathways in my experimental system?

To investigate BMP8A signaling pathways:

• Receptor activation studies:

  • BMP8A primarily signals through type I receptor BMPR1A/ALK6A and type II receptor BMPR2

  • Use co-immunoprecipitation (Co-IP) to confirm receptor-ligand interactions as demonstrated in zebrafish studies

  • Consider using dominant-negative ALK6A mutants to block signaling

• Downstream pathway analysis:

  • Smad-dependent pathway: Monitor phosphorylation of SMAD1/5/8 and SMAD2/3

  • Smad-independent pathway: Assess p38 MAPK activation, which is critical for BMP8A's antiviral effects

  • Western blotting for phosphorylated forms of these proteins provides temporal activation profiles

• Functional readouts:

  • Use IFN promoter-driven luciferase assays to measure activation of antiviral signaling

  • For cancer studies, assess cell proliferation, invasion, and drug resistance

  • In thermogenesis research, measure UCP1 expression and oxygen consumption rates

• Inhibitor experiments:

  • p38 MAPK inhibitors (e.g., SB203580) can confirm pathway involvement

  • Dorsomorphin can be used to inhibit BMP type I receptors

  • Assess pathway specificity by comparing effects of inhibitors on phosphorylation events

What are the challenges and solutions when investigating BMP8A in cancer models?

Studying BMP8A in cancer presents several methodological challenges:

• Expression heterogeneity:

  • Challenge: BMP8A expression varies significantly across cancer types and even within tumor subtypes

  • Solution: Stratify samples based on molecular subtypes (e.g., in breast cancer, separately analyze triple-negative, HER2+, luminal A, and luminal B)

• Distinguishing direct vs. indirect effects:

  • Challenge: Separating BMP8A-specific effects from other TGF-β family members

  • Solution: Use BMP8A knockdown/knockout combined with rescue experiments using recombinant BMP8A protein

• Microenvironment interactions:

  • Challenge: BMP8A functions may depend on the tumor microenvironment

  • Solution: Use conditional medium (CM) and tissue-specific extracts (e.g., bone matrix extract for bone metastasis studies) to mimic the microenvironment in vitro

• Pathway crosstalk:

  • Challenge: BMP8A interacts with multiple signaling pathways (Nrf2/TRIM24, Wnt, etc.)

  • Solution: Use ChIP-qPCR to identify direct transcriptional targets (e.g., TRIM24)

Sample data from TNBC studies:

How should I approach BMP8A protein interaction studies?

For investigating BMP8A protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Cell lysis: Use mild lysis buffers (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl pH 8.0) to preserve protein-protein interactions

  • Pre-clearing: Incubate lysates with protein A/G beads for 1 hour before antibody addition

  • Antibody incubation: Use 2-5 μg of anti-BMP8A antibody per mg of protein lysate

  • Controls: Include IgG control and input samples to verify specificity

  • Western blot: Probe for potential interaction partners (e.g., Alk6a, as demonstrated in zebrafish models)

• Proximity Ligation Assay (PLA):

  • Especially useful for detecting transient or weak interactions

  • Requires antibodies from different species for detection

  • Provides spatial information about interactions within cells

• Pull-down assays with tagged recombinant proteins:

  • Express His-tagged or GST-tagged BMP8A for pull-down experiments

  • Verify pull-down efficiency using ELISA or Western blot

  • Use mass spectrometry to identify novel binding partners

• Crosslinking approaches:

  • Use cell-permeable crosslinkers like DSP (dithiobis[succinimidylpropionate])

  • Apply 1-2 mM crosslinker for 30 minutes before cell lysis

  • Helps capture transient interactions that might be lost during standard Co-IP

How do I troubleshoot weak or non-specific signals in BMP8A immunodetection?

When encountering challenges with BMP8A antibodies:

• Weak signals:

  • Increase antibody concentration incrementally (e.g., from 1:1000 to 1:500)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use more sensitive detection systems (enhanced chemiluminescence)

  • Increase protein loading (up to 50-60 μg total protein)

  • For tissues with low expression, consider enrichment methods (e.g., immunoprecipitation before Western blotting)

• High background/non-specific binding:

  • Increase blocking time and concentration (5-10% blocking agent)

  • Use alternative blocking agents (BSA instead of milk, or vice versa)

  • Include 0.1-0.3% Triton X-100 in antibody diluent to reduce non-specific hydrophobic interactions

  • Perform additional washing steps (5 washes of 5 minutes each)

  • Decrease secondary antibody concentration

• Multiple bands in Western blotting:

  • Verify sample preparation (complete denaturation, fresh samples)

  • Check for post-translational modifications (phosphorylation, glycosylation)

  • Confirm antibody specificity with peptide competition assay

  • Use gradient gels for better separation of proteins

  • Consider testing different antibodies targeting different epitopes of BMP8A

What controls are essential for BMP8A research studies?

To ensure experimental rigor in BMP8A research:

• Positive controls:

  • Recombinant BMP8A protein for Western blotting

  • Tissues with known high expression (e.g., reproductive tissues, renal cell carcinoma)

  • Cells overexpressing BMP8A construct

• Negative controls:

  • Tissues from BMP8A knockout models when available

  • BMP8A-depleted cells (siRNA or CRISPR knockout)

  • Isotype control (rabbit IgG) for immunoprecipitation and immunohistochemistry

• Experimental validation controls:

  • For signaling studies: Positive controls like BMP2 or BMP4 treatment

  • For antibody specificity: Peptide competition assays

  • For functional studies: Established pathway inhibitors (e.g., dorsomorphin for BMP signaling)

• Technical controls:

  • Loading controls for Western blotting (β-actin, GAPDH)

  • Housekeeping genes for qPCR (GAPDH, β-actin, 18S rRNA)

  • Secondary antibody-only controls for IF/IHC to detect non-specific binding

How can I quantitatively assess BMP8A expression across different experimental conditions?

For rigorous quantification of BMP8A:

• Western blot densitometry:

  • Use linear range of detection for quantification

  • Normalize to loading controls (β-actin, GAPDH)

  • Use at least three biological replicates

  • Software recommendations: ImageJ, Image Lab, or similar quantification software

• qRT-PCR for mRNA expression:

  • Design primers spanning exon-exon junctions to avoid genomic DNA amplification

  • Recommended primer pairs:

    • Forward: 5'-CAGTCCAGCTGTAAGCCAAAG-3'

    • Reverse: 5'-GCTGTATCGCAGGCACTCT-3'

  • Use ΔΔCt method for relative quantification

  • Normalize to multiple reference genes for increased accuracy

• ELISA for secreted BMP8A:

  • Collect culture media after 24-48 hours of culture

  • Concentrate media if necessary using centrifugal filters

  • Analyze using sandwich ELISA technique

  • Standard curve range: 15.6-1000 pg/mL for accurate quantification

• Immunohistochemistry scoring:

  • Use established scoring systems (e.g., H-score = intensity × percentage of positive cells)

  • Have multiple independent observers score samples blind

  • Use digital image analysis software for unbiased quantification

How can I effectively study BMP8A in viral infection and immunity models?

Based on findings from zebrafish models, consider these approaches:

• Infection models:

  • For in vitro studies: Challenge cells (with or without BMP8A manipulation) with RNA viruses like GCRV or SVCV

  • For in vivo studies: Use either wild-type animals or BMP8A knockout models

  • Monitor viral load using qPCR, plaque assays, or cytopathic effect (CPE) assessment

• Signaling pathway analysis:

  • Focus on p38 MAPK-Tbk1-Irf3-IFN pathway components

  • Western blotting for phosphorylated forms of:

    • p38 MAPK (Thr180/Tyr182)

    • Tbk1 (Ser172)

    • Irf3 (Ser396)

  • Measure IFN production using ELISA or reporter assays

  • Use pathway inhibitors to confirm mechanism (SB203580 for p38 MAPK inhibition)

• Receptor interaction studies:

  • Co-immunoprecipitation of BMP8A with Alk6a receptor

  • Use dominant-negative Alk6a to block signaling

  • Assess downstream effects on antiviral immunity markers

• Functional readouts:

  • Measure type I IFN production

  • Assess expression of ISGs (Interferon-Stimulated Genes)

  • Monitor survival rates following viral challenge

  • Quantify viral load in various tissues

What methodology should I use when investigating BMP8A in cancer drug resistance mechanisms?

For studying BMP8A's role in drug resistance:

• Cell line models:

  • Compare parental cancer cell lines with:

    • BMP8A-overexpressing stable cell lines

    • BMP8A knockdown/knockout cell lines

  • Subject these lines to increasing doses of chemotherapeutic agents (e.g., As₂O₃ in renal cell carcinoma)

• Resistance pathway analysis:

  • Focus on Nrf2/TRIM24 axis and Wnt signaling

  • Measure expression and activation of key components:

    • Nrf2 phosphorylation status

    • TRIM24 expression levels

    • Wnt pathway components (β-catenin, GSK3β, p-GSK3β)

  • Use ChIP-qPCR to identify direct transcriptional targets

• ROS homeostasis assessment:

  • Measure ROS levels using fluorescent probes (e.g., DCF-DA)

  • Assess expression of ROS-regulating enzymes (e.g., SOD, catalase)

  • Determine if antioxidant treatment reverses BMP8A-mediated effects

• In vivo drug resistance models:

  • Establish xenograft models with BMP8A-manipulated cells

  • Treat with relevant chemotherapeutic agents

  • Monitor tumor volume, metastasis, and survival

  • Collect tumor tissue for molecular analysis

Key data from renal cell carcinoma studies:

How should I approach studying BMP8A in thermogenesis and energy metabolism?

For investigating BMP8A's role in thermogenesis:

• Cell culture models:

  • Use brown adipocytes (immortalized lines or primary cultures)

  • White-to-beige adipocyte conversion models

  • Hypothalamic cell lines for central effects

• Treatment protocols:

  • Recombinant BMP8A protein (50-200 ng/mL)

  • Adrenergic stimulators (e.g., isoproterenol, 10 μM)

  • Cold exposure for in vivo models (4-8°C for 4-24 hours)

• Readout parameters:

  • UCP1 expression (mRNA and protein levels)

  • Mitochondrial biogenesis markers (PGC-1α, NRF1, TFAM)

  • Oxygen consumption rate (OCR) using Seahorse analyzer

  • Thermogenic gene program (PRDM16, PGC-1α, Cidea)

  • In vivo measurements: body temperature, energy expenditure, cold tolerance

• Pathway investigations:

  • BMP receptor activation (BMPR1A/ALK6A and BMPR2)

  • p38 MAPK activation in adipocytes

  • Sympathetic output measurements for central effects

  • PKA activation and cAMP levels

What are the best approaches for investigating contradictory functions of BMP8A across different biological contexts?

To address the multifaceted and sometimes contradictory roles of BMP8A:

• Context-specific signaling analysis:

  • Compare signaling pathways across tissue types:

    • SMAD-dependent vs. SMAD-independent pathways

    • p38 MAPK activation in immune vs. metabolic tissues

    • Receptor expression profiling in different cell types

• Cell-type specific knockdown/knockout models:

  • Use tissue-specific promoters for conditional expression

  • Employ Cre-loxP systems for tissue-specific deletion

  • Compare effects across multiple tissue types within the same organism

• Interaction proteomics:

  • Perform BMP8A immunoprecipitation followed by mass spectrometry in different tissues

  • Compare interaction partners to identify tissue-specific cofactors

  • Validate key interactions with co-immunoprecipitation and proximity ligation assays

• Temporal dynamics assessment:

  • Analyze acute vs. chronic BMP8A exposure effects

  • Monitor signaling kinetics across different time points

  • Assess feedback regulation mechanisms in different contexts

This comparative approach will help reconcile seemingly contradictory functions of BMP8A in antiviral immunity, cancer progression, and metabolic regulation.

What are the emerging techniques that might advance BMP8A research?

Several cutting-edge approaches show promise for BMP8A research:

• CRISPR-based screening:

  • Genome-wide CRISPR screens to identify novel BMP8A interactors

  • CRISPRa/CRISPRi for refined expression modulation

  • Base editing for studying specific BMP8A mutations

• Single-cell technologies:

  • scRNA-seq to identify cell populations responsive to BMP8A

  • Spatial transcriptomics to map BMP8A expression in complex tissues

  • CyTOF for simultaneous assessment of multiple signaling pathways

• Organoid models:

  • Patient-derived organoids for personalized drug response studies

  • Multi-tissue organoids to study cross-talk between different cell types

  • Organoid-on-chip systems for dynamic pathway assessment

• In vivo imaging:

  • Bioluminescence resonance energy transfer (BRET) for real-time monitoring of BMP8A interactions

  • Intravital microscopy for tracking BMP8A signaling in live animals

  • PET imaging with radiolabeled BMP8A antibodies for whole-body distribution studies